Arch Oncology Ventures
Venture fund specializing in oncology therapeutics and cancer-focused biotech companies.
Arch is the real deal in life sciences - they've been doing this longer than almost anyone and have the exits to prove it. Their partners actually understand the science, not just the business model, which matters when you're betting on 10-year drug development timelines. They're patient capital with deep pockets and genuine operational expertise. The flip side? They're extremely selective and can be slow to move. If you're not Stanford/Harvard pedigreed or don't have a Nobel laureate on your team, getting their attention is tough. They also tend to take meaningful ownership stakes, so expect some control.
- —Best for: Deep-tech biotech with serious IP and long development cycles
- —Watch out for: High bar for entry and expect them to take significant equity
- —Known for: Patient capital, scientific rigor, and multiple biotech IPO successes
Arch Venture Partners focuses on early-stage life sciences investments, particularly in biotechnology, medical devices, and healthcare IT. They claim to partner with entrepreneurs to build transformative healthcare companies from the ground up.
Primarily Series A/B life sciences investor with occasional seed investments. Heavy focus on biotech, pharma, medical devices, and digital health. Chicago-based but invests nationally.
Former McKinsey consultant who co-founded Arch in 1986. Known as one of the most successful biotech VCs with multiple IPOs and exits. Respected for deep scientific knowledge and long-term thinking.
Former biotech executive and consultant with deep pharma industry connections. Joined Arch in 2000 and focuses on therapeutics investments. Known for hands-on operational support.
Former Genentech executive with drug development expertise. Joined Arch in 2012 and leads many of their oncology investments. Well-regarded for scientific rigor and strategic guidance.
Have a specific question about Arch Oncology Ventures?
Ask Bernie →